Cost-of-Illness Study for Non-Small-Cell Lung Cancer Using Real-World Data

Abstract

Background With recent advances in the treatment of non-small-cell lung cancer (nsclc) and current fiscal constraints within publicly funded health care systems, understanding the real-world economic effect of lung cancer management has become important. The objective of the present study was to determine the costs and resources used in the management of nsclc cohorts in Ontario.Methods Patients diagnosed between 1 April 2010 and 31 March 2015 were identified in the Ontario Cancer Registry and linked to provincial administrative databases, capturing resources such as hospitalizations, cancer clinic visits, physician services, and systemic therapies or radiotherapy. A cost-of-illness analysis using a bottom-up approach and the GETCOST macro available at ices determined the overall total and mean costs in 2017 Canadian dollars. Resource utilization results were analyzed according to the total number of encounters per resource, the number of patients using each resource, and the number of encounters per patient. A separate cost-and-resource analysis was conducted for radiotherapy.Results The 24,729 nsclc patients identified included 4542 with stage iii unresectable disease and 10,103 with stage iv nonsquamous disease. The overall total cost for all nsclc patients was $1.9 billion, with inpatient hospitalizations ($635.2 million), cancer clinic visits ($323.7 million), and physician services ($301.4 million) being the top cost contributors. The mean cost per patient was $76,816. The total cost of radiotherapy was $38.5 million.Conclusions Real-world costs for the management of nsclc during the 5-year period examined were substantial, despite the fact that median survival was poor and treatment information was limited.

Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model

“…In addition to the costs of lung cancer screening and the smoking cessation intervention, OncoSim includes costs of lung cancer treatment, estimated with the use of administrative data for patients with lung cancer in Ontario, supplemented with expert opinion (Appendix 1, section C). 15 The treatment costs included acute care, palliative care and end-of-life care.…”

Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model

“…Inflated to 2018 Canadian dollars, these costs are $57,687 and $58,330, respectively. A more recent study, also from Ontario, estimated the cost per diagnosed aNSCLC patient to be $68,887 ± 58,528 per patient (2018 Canadian dollars) [43]. These analyses pre-date the market availability of I-Os and TKIs other than erlotinib and gefitinib, but also the availability of generic versions of pemetrexed, gemcitabine, docetaxel and erlotinib.…”

Clinical Pharmacists in Chronic Care

“…Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80%-85% of all cases [401,402]. More than half of the NSCLC cases are diagnosed at an advanced stage (stages III and IV) [403,404]. Smoking causes at least 80% of lung cancer deaths [405].…”